NCT02476019View on ClinicalTrials.gov

A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

September 30, 2016

Conditions
Obesity
Interventions
DRUG

ISIS-FGFR4RX

ISIS-FGFR4RX administered subcutaneously

DRUG

Placebo

Placebo administered subcutaneously

Trial Locations (1)

32804

Translational Research Institute for Metabolism and Diabetes, Orlando

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY